Publication | Open Access
Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
31
Citations
29
References
2020
Year
Our findings suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1